期刊文献+

新型乙酰胆碱酯酶抑制剂的设计、合成与活性研究 被引量:6

Design, synthesis and evaluation of new acetylcholinesterase inhibitors
原文传递
导出
摘要 本文设计、合成了一类全新结构类型的2-氨基-4-苯基噻唑类化合物,并考察了这些化合物对乙酰胆碱酯酶活性的抑制作用。以α-溴代苯乙酮为起始原料,经Hantzsch、酰化和取代反应合成了2-氨基-4-苯基噻唑类化合物,并利用Ellman分光光度法考察了它们对乙酰胆碱酯酶(AChE)的体外抑制活性。实验结果表明目标化合物均具有一定的AChE抑制活性,其中化合物8a抑制活性最好,其IC50达到了3.54μmol·L-1,优于对照药利斯的明。2-氨基-4-苯基噻唑类化合物对乙酰胆碱酯酶具有较好的抑制活性,需要进一步深入研究。 A series of novel 2-amino-4-phenylthiazole derivatives were designed and synthesized, furthermore, their inhibition effect on acetylcholinesterase were investigated. 2-Amino-4-phenylthiazoles were prepared from a-bromoacetophenones by Hantzsch reaction, acylation reaction and substitution reaction. Moreover, their bioactivities as AChE inhibitors in vitro were measured with Ellman spectrophotometry. The results showed that most of them had a certain inhibition activity on ACHE, and the compound 8a was the best of them. The IC50 of 8a to AChE is 3.54 μmol·L^-1, and the value was better than that of rivastigmine. 2-Amino- 4-phenylthiazole derivatives showed a certain bioactivity in vitro, which were worth further investigation.
机构地区 河北大学药学院
出处 《药学学报》 CAS CSCD 北大核心 2014年第3期346-351,共6页 Acta Pharmaceutica Sinica
基金 国家"重大新药创制"科技重大专项资助项目(2012ZX09103-101-057) 国家自然科学基金资助项目(21175031) 河北省教育厅科研计划资助项目(ZD2010234) 河北省科技厅重点基础研究专项(11966411D)
关键词 2-氨基-4-苯基噻唑 乙酰胆碱酯酶抑制剂 阿尔茨海默病 2-amino-4-phenylthiazole acetylcholinesterase inhibitor Alzheimer's disease
  • 相关文献

参考文献1

二级参考文献48

  • 1Alzheimer A,Stelzmann RA,Schnitzlein HN,et al.AnEnglish translation of Alzheimer’s 1907 paper,“Uber eineeigenartige Erkankung der Hirnrinde”[J].Clin Anat,1995,8:429-431.
  • 2Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer’sdisease:progress and problems on the road to therapeutics[J].Science,2002,297:353-356.
  • 3Reddy PH.Mitochondrial oxidative damage in aging andAlzheimer’s disease:implications for mitochondrially targetedantioxidant therapeutics[J].J Biomed Biotechnol,2006,2006:31372.
  • 4Galasko D,Hansen LA,Katzman R,et al.Clinical-neuropathological correlations in Alzheimer’s disease andrelated dementias[J].Arch Neurol,1994,51:888-895.
  • 5Britschgi M,Rufibach K,Huang SL,et al.Modeling ofpathological traits in Alzheimer’s disease based on systemicextracellular signaling proteome[J].Mol Cell Proteomics,2011,10:M111.008862.
  • 6Consensus report of the Working Group on:“Molecular andBiochemical Markers of Alzheimer’s Disease”.The Ronaldand Nancy Reagan Research Institute of the Alzheimer’sAssociation and the National Institute on Aging WorkingGroup[J].Neurobiol Aging,1998,19:109-116.
  • 7Gosselet F,Candela P,Cecchelli R,et al.Role of theblood-brain barrier in Alzheimer’s disease[J].Med Sci(Paris),2011,27:987-992.
  • 8Blennow K,Hampel H.CSF markers for incipient Alzheimer’sdisease[J].Lancet Neurol,2003,2:605-613.
  • 9Strozyk D,Blennow K,White LR,et al.CSF Abeta 42 levelscorrelate with amyloid-neuropathology in a population-basedautopsy study[J].Neurology,2003,60:652-656.
  • 10Tapiola T,Alafuzoff I,Herukka SK,et al.Cerebrospinalfluid{beta}-amyloid 42 and tau proteins as biomarkers ofAlzheimer-type pathologic changes in the brain[J].ArchNeurol,2009,66:382-389.

共引文献3

同被引文献8

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部